Abstract:Abstract Background Controlling and limiting the expression of short hairpin RNA (shRNA) by using constitutive or tissue-specific polymerase II (pol II) expression can be a promising strategy to avoid RNAi toxicity. However, to date detailed studies on requirements for effective pol II shRNA expression and processing are not available. We investigated the optimal structural configuration of shRNA molecules, namely: hairpin location, stem length and termination signal required for effective pol II expression and compared it with an alternative strategy of avoiding toxicity by using artificial microRNA (miRNA) scaffolds. Results Highly effective shRNAs targeting luciferase (shLuc) or Apolipoprotein B100 (shApoB1 and shApoB2) were placed under the control of the pol II CMV promoter and expressed at +5 or +6 nucleotides (nt) with reference to the transcription start site (TSS). Different transcription termination signals (TTS), namely minimal polyadenylation (pA), poly T (T5) and U1 were also used. All pol II- expressed shRNA variants induced mild inhibition of Luciferase reporters carrying specific targets and none of them showed comparable efficacy to their polymerase III-expressed H1-shRNA controls, regardless of hairpin position and termination signal used. Extending hairpin stem length from 20 basepairs (bp) to 21, 25 or 29 bp yielded only slight improvement in the overall efficacy. When shLuc, shApoB1 and shApoB2 were placed in an artificial miRNA scaffold, two out of three were as potent as the H1-shRNA controls. Quantification of small interfering RNA (siRNA) molecules showed that the artificial miRNA constructs expressed less molecules than H1-shRNAs and that CMV-shRNA expressed the lowest amount of siRNA molecules suggesting that RNAi processing in this case is least effective. Furthermore, CMV-miApoB1 and CMV-miApoB2 were as effective as the corresponding H1-shApoB1 and H1-shApoB2 in inhibiting endogenous ApoB mRNA. Conclusion Our results demonstrate that artificial miRNA have a better efficacy profile than shRNA expressed either from H1 or CMV promoter and will be used in the future for RNAi therapeutic development.

Positional Effect of Short Interfering RNAs Expressing Vector Targeting Human RAB5A

RNA screening of efficient small interfering RNA target sites directed against truncated region of UL54 gene in human cytomegalovirus by small interfering RNA expression vectors

The Effects of Mutant Site G81R of RAB5A on RAB5A Function

Efficient Inhibition of Human Cytomegalovirus UL122 Gene Expression in Cell by Small Interfering RNAs

Small Interfering Rnas Targeting the Rabies Virus Nucleoprotein Gene

Construction and Functional Analysis of Short Interfering RNA Expression Vectors of Targeting Gene Apolipoprotein M

Secondary Structure of Target RNA Impacts on RNA Interference Efficiency

Shortening Pairing of the 3' Tail of shRNA with Target mRNA Reduces the Off-Target Effect

Effective and Accurate Gene Silencing by a Recombinant AAV-Compatible MicroRNA Scaffold.

Asymmetric Sirna: New Strategy to Improve Specificity and Reduce Off-Target Gene Expression.

[Construction and Selection of the Most Efficient Sirna Interfering Plasmid Specific to Mouse Qa-1 Gene].

Design, Screening and Evaluation of VEGF Sirna

Construction and Characterization of Crgd-Modified 9-Arginine Peptide As A Novel Vector for Targeted Sirna Delivery

STUDY ON INHIBITION OF EXPRESSION OF HUMAN NUCLEAR RECEPTOR NR5A2 VIA RNA INTERFERENCE MEDIATED BY SIRNA EXPRESSING VECTOR

Establishment of an expression vector of NgR-specific siRNA

Construction and Biological Evaluation of a Novel Integrin Ανβ3-Specific Carrier for Targeted Sirna Delivery in Vitro

Sirna Mediated Inhibition of Pancreatic Tumor Growth in Vitro and in Vivo

Inhibition of the Expression of RBPMS Gene by RNA Interference

RAB18 regulates extrahepatic siRNA-mediated gene silencing efficacy

Optimization and comparison of knockdown efficacy between polymerase II expressed shRNA and artificial miRNA targeting luciferase and Apolipoprotein B100

Establishment of experimental aminal model of RNAi in vivo using lentivirus-siRNA vector system targeting TFAM